Eric Zhi
Impact in
-
- Multiple Myeloma Research and Treatments
-
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
Papers in
- Oncology 9
- HER2/EGFR in Cancer Research 5
- Peptidase Inhibition and Analysis 2
- PARP inhibition in cancer therapy 2
-
- Advanced Breast Cancer Therapies 7
- Co-authors
- Douglas W. Sborov (2 shared papers)Ajay K. Nooka (3 shared papers)Erika Hamilton (4 shared papers)Attaya Suvannasankha (2 shared papers)Suzanne Trudel (2 shared papers)Ashraf Badros (3 shared papers)Adam D. Cohen (3 shared papers)Joanna Opalińska (3 shared papers)
- Journals
- ESMO Open (4 papers)Journal of Clinical Oncology (3 papers)Cancer Research (2 papers)Annals of Oncology (2 papers)Blood (1 paper)
- Partner nations
- United StatesSwitzerlandCanada
In The Last Decade
Eric Zhi
12 papers receiving 90 citations
Peers
Comparison fields: 5 of 17
- Hematology 42
- Oncology 48
- Pulmonary and Respiratory Medicine 23
- Reproductive Medicine 6
- Radiology, Nuclear Medicine and Imaging 13
Countries citing papers authored by Eric Zhi
This map shows the geographic impact of Eric Zhi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Zhi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Zhi more than expected).
Fields of papers citing papers by Eric Zhi
This network shows the impact of papers produced by Eric Zhi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Zhi. The network helps show where Eric Zhi may publish in the future.
Co-authors
The 25 scholars most cited alongside Eric Zhi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 25 | |
| 2 | 2023 | 13 | |
| 3 | 2020 | 13 | |
| 4 | 2022 | 10 | |
| 5 | 2024 | 7 | |
| 6 | 2024 | 7 | |
| 7 | 2023 | 6 | |
| 8 | 2023 | 4 | |
| 9 | 2023 | 3 | |
| 10 | 2024 | 2 | |
| 11 | 2020 | 1 | |
| 12 | 2021 | 1 | |
| 13 | 2019 | 0 |
About Eric Zhi
Eric Zhi is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Hematology and Organic Chemistry, having authored 13 papers that have together received 92 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (7 papers), Protein Degradation and Inhibitors (6 papers), HER2/EGFR in Cancer Research (5 papers), Multiple Myeloma Research and Treatments (3 papers), Peptidase Inhibition and Analysis (2 papers), PARP inhibition in cancer therapy (2 papers), Chronic Disease Management Strategies (1 paper) and Artificial Intelligence in Healthcare (1 paper). The work is most often cited by research in Hematology (42 citations), Oncology (48 citations), Pulmonary and Respiratory Medicine (23 citations), Reproductive Medicine (6 citations) and Radiology, Nuclear Medicine and Imaging (13 citations). Eric Zhi has collaborated with scholars based in United States, Switzerland and Canada. Frequent co-authors include Douglas W. Sborov, Ajay K. Nooka, Erika Hamilton, Attaya Suvannasankha, Suzanne Trudel, Ashraf Badros, Adam D. Cohen, Joanna Opalińska, Hyo S. Han and Ira Gupta. Their work appears in journals such as ESMO Open, Journal of Clinical Oncology, Cancer Research, Annals of Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.